ADMA Biologics, Inc. (ADMA) Profit Margins
Over the twelve months to 2026-06-30, ADMA Biologics, Inc. (ADMA) had gross margin 64.7%, operating margin 43.8%, net margin 33.0%, free cash flow margin 22.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ADMAADMA Biologics, Inc.Follow ADMA — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- 15.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 40.2% | 34.0% | 36.7% | 39.9% | 40.3% | -28.1% | -148.4% | -34.6% | -45.2% | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% | 64.7% | |
| Operating margin | -707.4% | -490.4% | -270.8% | -216.1% | -162.6% | -172.7% | -354.9% | -141.1% | -153.8% | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% | 43.8% | |
| Net margin | -653.0% | -506.2% | -284.2% | -250.4% | -183.1% | -192.3% | -387.1% | -164.5% | -179.4% | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% | 33.0% | |
| FCF margin | -628.1% | -361.3% | -287.9% | -215.2% | -172.1% | -175.5% | -381.4% | -272.6% | -271.7% | -155.5% | -47.6% | 1.6% | 25.9% | 5.5% | 22.7% |
USD millions · SEC XBRL
ADMA Biologics, Inc. — questions
- What is ADMA Biologics, Inc.'s gross margin?
- 64.7% over the twelve months to 2026-06-30.
- What is ADMA Biologics, Inc.'s operating margin?
- 43.8% over the twelve months to 2026-06-30.
- What is ADMA Biologics, Inc.'s net profit margin?
- 33.0% over the twelve months to 2026-06-30.
Every figure on this page comes from ADMA Biologics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.